HIV infection en route to endogenization: Two cases

Clinical Microbiology and Infection

Volumn 20, Issue 12, 2014, Pages 1280-1288

  Colson, P ^a,b   Ravaux, I ^c   Tamalet, C ^a,b   Glazunova, O ^b   Baptiste, E ^a   Chabriere, E ^a   Wiedemann, A ^d,e   Lacabaratz, C ^d,e   Chefrour, M ^b   Picard, C ^f   Stein, A ^b,c   Levy, Y ^d,e,g   Raoult, D ^a,b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b TIMONE HOSPITAL   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e Vaccine Research Institute (VRI)   (France)

^f AIX MARSEILLE UNIVERSITÉ   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

APOBEC; Cure; DNA integration; Endogenization; Endogenous retrovirus; Human immunodeficiency virus; Stop codon; Tryptophan; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; TRYPTOPHAN; STOP CODON; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; FLOW CYTOMETRY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STOP CODON; VIRAL CLEARANCE; VIRUS TRANSFORMATION; YOUNG ADULT; ENDOGENOUS RETROVIRUS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; PROVIRUS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; MAMMALIA; VERTEBRATA;

CODON, NONSENSE; CODON, TERMINATOR; COHORT STUDIES; DNA, VIRAL; ENDOGENOUS RETROVIRUSES; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROVIRUSES; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84920446243     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12807     Document Type: Article

References (30)

1. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/AIDS. AIDS 2012; 26: 1205-1213.
2. Barre-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol 2013; 11: 877-883.
3. Fauci AS, Marston HD, Folkers GK. An HIV cure: feasibility, discovery, and implementation. JAMA 2014; 312: 335-336.
4. Hutter G, Nowak D, Mossner M et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
5. Pantaleo G, Menzo S, Vaccarezza M et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209-216.
6. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27: 406-416.
7. Lambotte O, Boufassa F, Madec Y et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41: 1053-1056.
8. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6: 181-187.
9. Tamalet C, Masquelier B, Ferchal F et al. Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titres. AIDS 1992; 6: 1403-1404.
10. Avettand-Fenoel V, Prazuck T, Hocqueloux L et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 2008; 22: 1880-1882.
11. Eyzaguirre LM, Charurat M, Redfield RR, Blattner WA, Carr JK, Sajadi MM. Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology 2013; 443: 306-312.
12. Wolk T, Schreiber M. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med Microbiol Immunol 2006; 195: 165-172.
13. Shytaj IL, Savarino A. A cure for AIDS: a matter of timing? Retrovirology 2013; 10: 145.
14. Makarova KS, Haft DH, Barrangou R et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 2011; 9: 467-477.
15. Stoye JP. Studies of endogenous retroviruses reveal a continuing evolutionary saga. Nat Rev Microbiol 2012; 10: 395-406.
16. Liu H, Fu Y, Xie J et al. Widespread endogenization of densoviruses and parvoviruses in animal and human genomes. J Virol 2011; 85: 9863-9876.
17. Raoult D. A viral grandfather: genomics in 2010 contradict Darwin's vision of evolution. Eur J Clin Microbiol Infect Dis 2011; 30: 935-936.
18. Mi S, Lee X, Li X et al. Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature 2000; 403: 785-789.
19. Tarlinton RE, Meers J, Young PR. Retroviral invasion of the koala genome. Nature 2006; 442: 79-81.
20. Oliveira NM, Farrell KB, Eiden MV. In vitro characterization of a koala retrovirus. J Virol 2006; 80: 3104-3107.
21. Lim ES, Emerman M. HIV: going for the watchman. Nature 2011; 474: 587-588.
22. Viginier B, Dolmazon C, Lantier I et al. Copy number variation and differential expression of a protective endogenous retrovirus in sheep. PLoS ONE 2012; 7: e41965.
23. Takeda A, Matano T. Inhibition of infectious murine leukemia virus production by Fv-4 env gene products exerting dominant negative effect on viral envelope glycoprotein. Microbes Infect 2007; 9: 1590-1596.
24. Sandler NG, Bosinger SE, Estes JD et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511: 601-605.
25. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004; 4: 868-877.
26. Lee YN, Malim MH, Bieniasz PD. Hypermutation of an ancient human retrovirus by APOBEC3G. J Virol 2008; 82: 8762-8770.
27. Bonvin M, Achermann F, Greeve I et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-1374.
28. Wang Z, Luo Y, Shao Q et al. Heat-stable molecule derived from Streptococcus cristatus induces APOBEC3 expression and inhibits HIV-1 replication. PLoS One 2014; 9: e106078.
29. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279: 7792-7798.
30. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006; 80: 3112-3115.